Bavisant dihydrochloride is under clinical development by BenevolentAI and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bavisant dihydrochloride’s likelihood of approval (LoA) and phase transition for Hypersomnia took place on 11 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bavisant dihydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bavisant dihydrochloride overview

Bavisant dihydrochloride (BEN-2001, JNJ-31001074) is under development for the treatment of excessive daytime sleepiness (EDS) in patients with Parkinson's disease. The drug candidate is administered orally as a tablet. It targets H3 receptor and is developed using artificial intelligence technology. It was also under development for the treatment of attention-deficit/hyperactivity disorder (ADHD) and alcohol dependence.

BenevolentAI overview

BenevolentAI is a drug discovery company. It carries out developing and applying artificial intelligence (AI) to produce new medicines for the treatment of diseases. The company’s drug programs include BEN2293 (atopic dermatitis), BEN8744 (ulcerative colitis), BEN9160 (amyotrophic lateral sclerosis), glioblastoma multiforme, inflammatory bowel disease, CNS diseases, antiviral, nonalcoholic steatohepatitis (NASH), oncology, Parkinson’s disease, chronic kidney disease, idiopathic pulmonary fibrosis, and others. BenevolentAI’s platform enables scientists to design and develop new treatments for patients, using a large amount of extracted and deduced biomedical information. The company operates in the UK and the US. BenevolentAI is headquartered in London, England, the UK.

Quick View Bavisant dihydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Bavisant dihydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.